Predicting biopsy-proven prostate cancer recurrence following cryosurgery

Jorge R. Caso, Matvey Tsivian, Vladimir Mouraviev, Thomas J. Polascik

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: Prostate cancer (CaP) cryosurgery utilizes PSA nadir level and radiotherapy criteria as surrogates for success. We attempted to correlate PSA doubling time (PSAdt) and time of undetectable PSA (TUPSA) with biopsy-proven cancer recurrence (BPR) in men treated with primary third-generation cryotherapy for clinically localized CaP. Materials and methods: Demographic, clinical, and pathologic data was retrieved including age, race, use of preoperative hormones or 5-α reductase inhibitors (5-ARIs), initial biopsy PSA, biopsy Gleason score, cT stage, prostate volume, presence/absence median lobe, and follow-up. Post-cryotherapy biopsy was considered for PSA levels ≥ 0.5 ng/ml. PSAdt was determined by the log-slope method. TUPSA was defined as time from surgery to a PSA value ≥ 0.2ng/ml or most recent follow-up if undetectable. Results: Ninety-seven patients were identified. Preoperative hormonal manipulation was used in 25 (26%); 5 (5%) were using a 5-ARI. Twenty-seven (29%) underwent post-cryotherapy biopsy, 12 (12%) had a BPR. In 41 (42%), PSAdt was calculated (median 11.9 months, IQR 6.6-34.8); no significant difference between patients with BPR and without CaP was found (P = 0.46). TUPSA was a median of 4.9 months (IQR 3.2-9.9) vs. 15.6 months (IQR 6.1-30.3) for BPR or no CaP, respectively (P = 0.005). On proportional hazards regression, TUPSA was the only independent predictor of BPR (P = 0.03, OR 0.91). Conclusions: Post-cryosurgery PSAdt does not appear to be associated with BPR risk, whereas TUPSA reduces the risk of BPR by 9% per month. This may help guide management if local failure is suspected.

Original languageEnglish
Pages (from-to)391-395
Number of pages5
JournalUrologic Oncology: Seminars and Original Investigations
Volume30
Issue number4
DOIs
StatePublished - Jul 1 2012

Fingerprint

Cryosurgery
Prostatic Neoplasms
Biopsy
Recurrence
Cryotherapy
Neoplasms
Neoplasm Grading
Prostate
Oxidoreductases
Radiotherapy
Demography
Hormones

Keywords

  • Cryosurgery
  • Prostate cancer
  • Prostate-specific antigen
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Predicting biopsy-proven prostate cancer recurrence following cryosurgery. / Caso, Jorge R.; Tsivian, Matvey; Mouraviev, Vladimir; Polascik, Thomas J.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 30, No. 4, 01.07.2012, p. 391-395.

Research output: Contribution to journalArticle

Caso, Jorge R. ; Tsivian, Matvey ; Mouraviev, Vladimir ; Polascik, Thomas J. / Predicting biopsy-proven prostate cancer recurrence following cryosurgery. In: Urologic Oncology: Seminars and Original Investigations. 2012 ; Vol. 30, No. 4. pp. 391-395.
@article{fb57462b2b6940a99ba36247ec75e3bf,
title = "Predicting biopsy-proven prostate cancer recurrence following cryosurgery",
abstract = "Objectives: Prostate cancer (CaP) cryosurgery utilizes PSA nadir level and radiotherapy criteria as surrogates for success. We attempted to correlate PSA doubling time (PSAdt) and time of undetectable PSA (TUPSA) with biopsy-proven cancer recurrence (BPR) in men treated with primary third-generation cryotherapy for clinically localized CaP. Materials and methods: Demographic, clinical, and pathologic data was retrieved including age, race, use of preoperative hormones or 5-α reductase inhibitors (5-ARIs), initial biopsy PSA, biopsy Gleason score, cT stage, prostate volume, presence/absence median lobe, and follow-up. Post-cryotherapy biopsy was considered for PSA levels ≥ 0.5 ng/ml. PSAdt was determined by the log-slope method. TUPSA was defined as time from surgery to a PSA value ≥ 0.2ng/ml or most recent follow-up if undetectable. Results: Ninety-seven patients were identified. Preoperative hormonal manipulation was used in 25 (26{\%}); 5 (5{\%}) were using a 5-ARI. Twenty-seven (29{\%}) underwent post-cryotherapy biopsy, 12 (12{\%}) had a BPR. In 41 (42{\%}), PSAdt was calculated (median 11.9 months, IQR 6.6-34.8); no significant difference between patients with BPR and without CaP was found (P = 0.46). TUPSA was a median of 4.9 months (IQR 3.2-9.9) vs. 15.6 months (IQR 6.1-30.3) for BPR or no CaP, respectively (P = 0.005). On proportional hazards regression, TUPSA was the only independent predictor of BPR (P = 0.03, OR 0.91). Conclusions: Post-cryosurgery PSAdt does not appear to be associated with BPR risk, whereas TUPSA reduces the risk of BPR by 9{\%} per month. This may help guide management if local failure is suspected.",
keywords = "Cryosurgery, Prostate cancer, Prostate-specific antigen, Recurrence",
author = "Caso, {Jorge R.} and Matvey Tsivian and Vladimir Mouraviev and Polascik, {Thomas J.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.urolonc.2010.04.001",
language = "English",
volume = "30",
pages = "391--395",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Predicting biopsy-proven prostate cancer recurrence following cryosurgery

AU - Caso, Jorge R.

AU - Tsivian, Matvey

AU - Mouraviev, Vladimir

AU - Polascik, Thomas J.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Objectives: Prostate cancer (CaP) cryosurgery utilizes PSA nadir level and radiotherapy criteria as surrogates for success. We attempted to correlate PSA doubling time (PSAdt) and time of undetectable PSA (TUPSA) with biopsy-proven cancer recurrence (BPR) in men treated with primary third-generation cryotherapy for clinically localized CaP. Materials and methods: Demographic, clinical, and pathologic data was retrieved including age, race, use of preoperative hormones or 5-α reductase inhibitors (5-ARIs), initial biopsy PSA, biopsy Gleason score, cT stage, prostate volume, presence/absence median lobe, and follow-up. Post-cryotherapy biopsy was considered for PSA levels ≥ 0.5 ng/ml. PSAdt was determined by the log-slope method. TUPSA was defined as time from surgery to a PSA value ≥ 0.2ng/ml or most recent follow-up if undetectable. Results: Ninety-seven patients were identified. Preoperative hormonal manipulation was used in 25 (26%); 5 (5%) were using a 5-ARI. Twenty-seven (29%) underwent post-cryotherapy biopsy, 12 (12%) had a BPR. In 41 (42%), PSAdt was calculated (median 11.9 months, IQR 6.6-34.8); no significant difference between patients with BPR and without CaP was found (P = 0.46). TUPSA was a median of 4.9 months (IQR 3.2-9.9) vs. 15.6 months (IQR 6.1-30.3) for BPR or no CaP, respectively (P = 0.005). On proportional hazards regression, TUPSA was the only independent predictor of BPR (P = 0.03, OR 0.91). Conclusions: Post-cryosurgery PSAdt does not appear to be associated with BPR risk, whereas TUPSA reduces the risk of BPR by 9% per month. This may help guide management if local failure is suspected.

AB - Objectives: Prostate cancer (CaP) cryosurgery utilizes PSA nadir level and radiotherapy criteria as surrogates for success. We attempted to correlate PSA doubling time (PSAdt) and time of undetectable PSA (TUPSA) with biopsy-proven cancer recurrence (BPR) in men treated with primary third-generation cryotherapy for clinically localized CaP. Materials and methods: Demographic, clinical, and pathologic data was retrieved including age, race, use of preoperative hormones or 5-α reductase inhibitors (5-ARIs), initial biopsy PSA, biopsy Gleason score, cT stage, prostate volume, presence/absence median lobe, and follow-up. Post-cryotherapy biopsy was considered for PSA levels ≥ 0.5 ng/ml. PSAdt was determined by the log-slope method. TUPSA was defined as time from surgery to a PSA value ≥ 0.2ng/ml or most recent follow-up if undetectable. Results: Ninety-seven patients were identified. Preoperative hormonal manipulation was used in 25 (26%); 5 (5%) were using a 5-ARI. Twenty-seven (29%) underwent post-cryotherapy biopsy, 12 (12%) had a BPR. In 41 (42%), PSAdt was calculated (median 11.9 months, IQR 6.6-34.8); no significant difference between patients with BPR and without CaP was found (P = 0.46). TUPSA was a median of 4.9 months (IQR 3.2-9.9) vs. 15.6 months (IQR 6.1-30.3) for BPR or no CaP, respectively (P = 0.005). On proportional hazards regression, TUPSA was the only independent predictor of BPR (P = 0.03, OR 0.91). Conclusions: Post-cryosurgery PSAdt does not appear to be associated with BPR risk, whereas TUPSA reduces the risk of BPR by 9% per month. This may help guide management if local failure is suspected.

KW - Cryosurgery

KW - Prostate cancer

KW - Prostate-specific antigen

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84862985084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862985084&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2010.04.001

DO - 10.1016/j.urolonc.2010.04.001

M3 - Article

C2 - 20826095

AN - SCOPUS:84862985084

VL - 30

SP - 391

EP - 395

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 4

ER -